Apogee Therapeutics, Inc. announced two abstracts co-written with Apogee?s research partner, Paragon Therapeutics, Inc., highlighting the company?s lead product candidate, APG777, a fully optimized and half-life extended antibody targeting IL-13 for the treatment of AD, have been accepted as e-posters at the upcoming 2023 European Academy of Dermatology and Venereology (EADV) Congress, held October 11-14, 2023, in Berlin, Germany and virtually.